Eun Jin Jang1, Jung Eun Ha2, Seul Gi Im3, Myeong Gyu Kim4, Hyun Soon Sohn5. 1. College of Natural Sciences, Andong National University, Andong, Gyeongsangbuk-do, South Korea. 2. College of Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea. 3. College of Natural Sciences, Kyungpook National University, Daegu, South Korea. 4. Graduate School of Clinical Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea. 5. College of Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea. sohn64@cha.ac.kr.
Abstract
BACKGROUND AND OBJECTIVES: Anti-tumor necrosis factor alpha (anti-TNFα) therapy is key to the treatment of inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD). The objective of this study was to investigate prescribing patterns and non-persistence of anti-TNFα therapy for the treatment of IBD in a real-world scenario. METHODS: Data from the Korean National Health Insurance claims database obtained between 2010 and 2014 were evaluated to identify patients with IBD who had received anti-TNFα therapy (infliximab or adalimumab). Patient characteristics and prescribing patterns were investigated. The non-persistence rate and associated reasons were determined in patients who initiated therapy between 2010 and 2012. RESULTS: A total of 131,158 patients with UC and 57,286 with CD were identified. Of these 1747 UC (1.3%) and 3731 (6.5%) CD patients had received anti-TNFα therapy and were included in the analysis. Infliximab was prescribed more frequently than adalimumab (84.6% vs 15.4% in UC and 80.7% vs 19.4% in CD); 81.0% of UC and 72.0% of CD patients received anti-TNFα alone or in combination with 5-aminosalicylic acid. The non-persistence rate of anti-TNFα therapy was 72.6% and 80.4% in the UC and CD groups, respectively, with discontinuation of medication being the most common reason in both the UC and CD groups (63.9% and 73.3%, respectively). CONCLUSION: The use of anti-TNFα therapy was seen to be low, with a high rate of non-persistence. Further research efforts are required to improve the response rate and, therefore, improve persistence in patients with IBD.
BACKGROUND AND OBJECTIVES: Anti-tumor necrosis factor alpha (anti-TNFα) therapy is key to the treatment of inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD). The objective of this study was to investigate prescribing patterns and non-persistence of anti-TNFα therapy for the treatment of IBD in a real-world scenario. METHODS: Data from the Korean National Health Insurance claims database obtained between 2010 and 2014 were evaluated to identify patients with IBD who had received anti-TNFα therapy (infliximab or adalimumab). Patient characteristics and prescribing patterns were investigated. The non-persistence rate and associated reasons were determined in patients who initiated therapy between 2010 and 2012. RESULTS: A total of 131,158 patients with UC and 57,286 with CD were identified. Of these 1747 UC (1.3%) and 3731 (6.5%) CDpatients had received anti-TNFα therapy and were included in the analysis. Infliximab was prescribed more frequently than adalimumab (84.6% vs 15.4% in UC and 80.7% vs 19.4% in CD); 81.0% of UC and 72.0% of CDpatients received anti-TNFα alone or in combination with 5-aminosalicylic acid. The non-persistence rate of anti-TNFα therapy was 72.6% and 80.4% in the UC and CD groups, respectively, with discontinuation of medication being the most common reason in both the UC and CD groups (63.9% and 73.3%, respectively). CONCLUSION: The use of anti-TNFα therapy was seen to be low, with a high rate of non-persistence. Further research efforts are required to improve the response rate and, therefore, improve persistence in patients with IBD.
Authors: Hyun Jung Kim; Hoo Jae Hann; Sung No Hong; Kyoung Hoon Kim; Il Min Ahn; Ji Yang Song; Sang Hyuk Lee; Hyeong Sik Ahn Journal: Inflamm Bowel Dis Date: 2015-03 Impact factor: 5.325
Authors: Natalie A Molodecky; Ing Shian Soon; Doreen M Rabi; William A Ghali; Mollie Ferris; Greg Chernoff; Eric I Benchimol; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Gilaad G Kaplan Journal: Gastroenterology Date: 2011-10-14 Impact factor: 22.682
Authors: Siew C Ng; Whitney Tang; Jessica Y Ching; May Wong; Chung Mo Chow; A J Hui; T C Wong; Vincent K Leung; Steve W Tsang; Hon Ho Yu; Mo Fong Li; Ka Kei Ng; Michael A Kamm; Corrie Studd; Sally Bell; Rupert Leong; H Janaka de Silva; Anuradhani Kasturiratne; M N F Mufeena; Khoon Lin Ling; Choon Jin Ooi; Poh Seng Tan; David Ong; Khean L Goh; Ida Hilmi; Pises Pisespongsa; Sathaporn Manatsathit; Rungsun Rerknimitr; Satimai Aniwan; Yu Fang Wang; Qin Ouyang; Zhirong Zeng; Zhenhua Zhu; Min Hu Chen; Pin Jin Hu; Kaichun Wu; Xin Wang; Marcellus Simadibrata; Murdani Abdullah; Justin Cy Wu; Joseph J Y Sung; Francis K L Chan Journal: Gastroenterology Date: 2013-04-09 Impact factor: 22.682
Authors: Jae Jun Park; Suk-Kyun Yang; Byong Duk Ye; Jong Wook Kim; Dong Il Park; Hyuk Yoon; Jong Pil Im; Kang Moon Lee; Sang Nam Yoon; Heeyoung Lee Journal: Intest Res Date: 2017-01-31
Authors: Chang Hwan Choi; Won Moon; You Sun Kim; Eun Soo Kim; Bo-In Lee; Yunho Jung; Yong Sik Yoon; Heeyoung Lee; Dong Il Park; Dong Soo Han Journal: Intest Res Date: 2017-01-31